Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Helmut Woelk Klinik für Psychiatrie und Psychotherapie,
Akademisches Lehrkrankenhaus der Universität Giessen, Licher Strasse
106, D-35394 Giessen, Germany
Objectives:
To compare the efficacy and tolerability
of Hypericum perforatum (St John's wort extract) with
imipramine in patients with mild to moderate depression.
Design:
Randomised, multicentre, double blind,
parallel group trial.
Setting:
40 outpatient clinics in Germany.
Participants:
324 outpatients with mild to moderate depression.
Intervention:
75 mg imipramine twice daily or 250 mg
hypericum extract ZE 117 twice daily for 6 weeks.
Main outcome measures:
Hamilton depression rating
scale, clinical global impression scale, and patient's global
impression scale.
Results:
Among the 157 participants taking hypericum mean scores on the Hamilton depression scale decreased from 22.4 at
baseline to 12.00 at end point; among the 167 participants taking
imipramine they fell from 22.1 to 12.75. Mean clinical global
impression scores at end point were 2.22 out of 7 for the hypericum group and 2.42 for the imipramine group. On the 7 point self
assessments of global improvement completed by participants (score of 1 indicating "very much improved" and 7 indicating "very much
deteriorated") mean scores were 2.44 in the hypericum group and 2.60 in the imipramine group. None of the differences between treatment
groups were significant. However, the mean score on the
anxiety-somatisation subscale of the Hamilton scale (3.79 in the
hypericum group and 4.26 in the imipramine group) indicated a
significant advantage for hypericum relative to imipramine. Mean scores
on the 5 point scale used by participants to assess tolerability (score
of 1 indicating excellent tolerability and 5 indicating very poor
tolerability) were better for hypericum (1.67) than imipramine (2.35).
Adverse events occurred in 62/157 (39%) participants taking
hypericum and in 105/167 (63%) taking imipramine. 4 (3%)
participants taking hypericum withdrew because of adverse events
compared with 26 (16%) taking imipramine.
Conclusions:
This Hypericum perforatum
extract is therapeutically equivalent to imipramine in treating mild to
moderate depression, but patients tolerate hypericum better.
© BMJ 2000
Read all Rapid Responses